View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 4, 2018

Sanofi to open R&D hub in Chengdu, China

Global biopharmaceutical company Sanofi has announced plans to establish a global research and development (R&D) operations hub in Chengdu, China with an investment of €66m.

By Allie Nawrat

Global biopharmaceutical company Sanofi has announced plans to establish a global research and development (R&D) operations hub in Chengdu, China with an investment of €66m.

The main focus of the hub will be supporting Sanofi’s drug development by managing multi-centre clinical trials, accelerating the analysis of trial data and using innovative technology, such as gene therapy, multi-specific antibodies and polypeptide technology.

Sanofi also plans to use the hub to tackle therapeutic areas including vaccines, immunology and inflammation, multiple sclerosis and cardiovascular diseases.

This move confirms China as the third pillar of Sanofi’s clinical sciences and operations alongside the US and France. The new Chengdu location adds to the existing 11 regional offices and three production bases in the country, which have been established under the Sanofi China brand since 1982.

The company claims it wants to take advantage of local talent in pharmaceutical R&D and aims to recruit 300 professionals by 2020.

Sanofi senior vice-president and R&D operations global head Zhang Zi said: “Through this new Hub, we will take full advantage of our global experience and R&D capabilities together with local scientific research strengths to further improve innovation.

“Our goal is to link China’s innovative achievements with the global ecosystem and develop innovative drugs in China that could benefit patients around the world.”

This investment in Chengdu follows Sanofi’s integration of its infectious disease unit into German drug discovery company Evotec for €60m in July and acquisition of nanotechnology company Ablynx for $3.9bn in June.

The purchase of Ablynx is expected by the company to support its R&D programmes. Sanofi CEO Olivier Brandicourt said: “With Ablynx, we continue to advance the strategic transformation of our Research and Development, expanding our late-stage pipeline and strengthening our platform for growth in rare blood disorders.

The French biopharmaceutical company also sold its generic drugs business Zentiva to Advent for €1.9bn. Zentiva is based in the Czech Republic and serves more than 40 million patients across 25 European countries.

 

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU